Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

31.03.2021 | short review | Ausgabe 2/2021 Open Access

memo - Magazine of European Medical Oncology 2/2021

Novel immune checkpoints beyond PD-1 in advanced melanoma

memo - Magazine of European Medical Oncology > Ausgabe 2/2021
Nina Zila, Christoph Hoeller, Verena Paulitschke
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


In malignant diseases, targeting of immune checkpoints successfully changed the therapeutic landscape and helped to unleash anti-tumor T cell responses, resulting in durable clinical outcomes, but only in up to 50% of patients. The success of these therapies and the need to overcome intrinsic and acquired therapy resistance stimulated research to identify new pathways and targets. Numerous clinical trials are currently evaluating novel checkpoint inhibitors or recently developed strategies like modulating the tumor microenvironment, mostly in combination with approved therapies. This short review briefly discusses promising therapeutic targets, currently still under investigation, with the chance to realize clinical application in the foreseeable future.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 2/2021

memo - Magazine of European Medical Oncology 2/2021 Zur Ausgabe